Minggu, 15 Desember 2019

Villains or visionaries? Hedge funds short companies they say 'greenwash' - Reuters

LONDON (Reuters) - Tens of trillions of global investment dollars are pouring into companies touting robust environmental, social and governance credentials. Now short-sellers spy an opportunity.

FILE PHOTO: Carson Block, Chief Investment Officer, Muddy Waters Capital LLC., speaks at the Sohn Investment Conference in New York City, U.S. May 4, 2016. REUTERS/Brendan McDermid/File Photo

Such hedge funds, often cast as villains of the piece because they bet against share prices, scent a profit from company valuations they believe are unduly inflated by ESG promises or which they say ignore risks that threaten to undermine the company’s prospects.

The fact short-sellers, who look to exploit information gaps, are targeting the ESG sphere underlines the complexities facing investors in accurately gauging companies’ sustainability credentials. Teenage climate activist Greta Thunberg last week spoke of CEOs masking inaction with “creative PR”.

Against a backdrop of growing public and political concerns about climate change and economic inequality, companies are under increasing pressure to show they are taking greater responsibility for how they generate their profits.

Investments defined as “sustainable” account for more than a quarter of all assets under management globally, according to the Global Sustainable Investment Alliance. About $31 trillion has been invested, buoyed by analyst reports that show companies with strong ESG narratives outperform their peers.

Some short-sellers, including Carson Block of Muddy Waters, Josh Strauss of Appleseed Capital and Chad Slater of Morphic Asset Management, argue share prices can be bolstered by corporate misrepresentation about sustainability, or so-called “greenwashing”.

“Greenwashing is absolutely rampant now,” says Slater, whose fund bets on both rising and falling share prices. If companies fail to engage with long-term investors, he sees a red flag.

“From the short side, it’s quite interesting.”

Analytics companies that provide corporate ESG ratings use a combination of company disclosures, news sources and qualitative analysis of third-party data. They are a major source of information for investors, but it is not an exact science.

Hedge funds have various strategies for selecting targets, often focusing on those they think show both ESG and more traditional financial or operational weakness. A high ESG rating can attract short interest.

A Reuters analysis of data from financial information company Refinitiv and national regulators in Britain, France, Germany, Spain and Italy shows the five companies in each country with the best ESG scores collectively were being shorted more than those with the worst scores.

The short positions against the companies deemed to have the best ESG credentials were 50% greater in size than those placed against the worst-performers.

(Graphic: ESG shorts - UK: here)

For an interactive version of the graphic, click here tmsnrt.rs/2RwpBDj. For additional graphics covering the other countries mentioned, see related content.

PATCHY DATA

ESG data providers compile ratings based on a slew of measures ranging from energy usage to board gender make-up, salary gap data and the scale of negative press reports on the company from newspapers across the world.

Refinitiv, part-owned by the parent company of Reuters News, factors in more than 400 ESG measures for each company, taken from a range of sources including company reports, regulatory filings, NGO websites and news articles.

A key problem, though, is scant regulations governing what ESG measures and risks companies must disclose and their patchy nature, said Diederik Timmer, executive vice president of client relations at Sustainalytics, a major ESG data provider.

    “When things go well, companies report quite well on those, when things don’t go so well it gets awfully quiet,” he added.

Some policymakers, largely in Europe, are pushing for standardized disclosures to help investors better gauge the risks, something which will leave less wriggle room for companies and make scores even more reliable.

    Two leading global asset managers interviewed by Reuters, who manage nearly $1 trillion in assets but declined to be identified, said they had tested their portfolios using several data providers and found the correlation between ESG ratings to be so low, they are building their own ranking system.

Peter Hafez, chief data scientist at RavenPack, which helps hedge funds analyze data to get a trading edge, agreed.

“There’s no perfect ESG rating out there,” he said.

The influence of news flows on investor sentiment was underlined by a Deutsche Bank study here published in September that mapped 1,600 stocks and millions of company announcements and climate-related media reports over two decades.

It found companies that had a greater proportion of positive announcements and press over the preceding 12 months outperformed the MSCI World Index by 1.4% a year, on average, while those with more negative news underperformed by 0.3%.

For graphics of the data, click here tmsnrt.rs/2ncsFY0 and here tmsnrt.rs/2nd5hcT.

BIG RISKS FOR SHORTS

Short-sellers borrow shares, pay the lender a fee and sell them on, betting the price will fall before buying them back and returning them to the original lender - pocketing the difference, minus the fee.

But it is not for the faint-hearted. If funds trigger a share price fall, they can earn millions, but the downside, should shares rise, is unlimited.

The perils of the practice were shown by the shorts burnt by a 17% surge in the shares of Elon Musk’s Tesla in October after a surprise quarterly profit. Short-sellers suffered paper losses of $1.4 billion, erasing most of their 2019 profits, according to analytics firm S3 Partners.

And in a decade-long stock market bull-run, short-selling can be tricky.

Morphic’s joint chief investment officer Slater said the Sydney-based money manager’s standalone short positions in its Trium Morphic ESG long-short fund had weighed on the portfolio over the past 12 months.

Niche activist short-sellers, who can torpedo company valuations by publishing negative reports on targets - often alleging fraud or serious failures - are often criticized for undermining long-term company objectives and blurring the lines between whistleblower and market manipulator.

Short-sellers agree they are biased, but argue no more than long investors, the banks that raise money for the company and the company’s management.

Carson Block, founder of American short-seller Muddy Waters, who shot to prominence spotting wrongdoing in some Chinese-run companies, is now seeking a “morality short” on ESG - branching out from a traditional focus on corporate governance issues to targets whose success he says hinges on secretly harming society.

As an example of what he is seeking, he points to the U.S. opioid crisis, which has triggered around 2,500 lawsuits by authorities seeking to hold drugmakers responsible for stoking a scandal that has claimed almost 400,000 overdose deaths between 1999 and 2017.

“I’m really skeptical of ESG,” he says, likening the use of the acronym by the corporate world to the token straw slipped into a large plastic cup with a plastic lid.

“ESG is the paper straw of investing,” he says. “I definitely want to find companies like that because I know they’re out there and I want to help put them down.”

Reporting by Kirstin Ridley and Simon Jessop; Editing by Pravin Char

Let's block ads! (Why?)


https://news.google.com/__i/rss/rd/articles/CBMinQFodHRwczovL3d3dy5yZXV0ZXJzLmNvbS9hcnRpY2xlL3VzLWdsb2JhbC1oZWRnZWZ1bmRzLXN1c3RhaW5hYmxlLWFuYWx5c2kvdmlsbGFpbnMtb3ItdmlzaW9uYXJpZXMtaGVkZ2UtZnVuZHMtc2hvcnQtY29tcGFuaWVzLXRoZXktc2F5LWdyZWVud2FzaC1pZFVTS0JOMVlKMDk30gE0aHR0cHM6Ly9tb2JpbGUucmV1dGVycy5jb20vYXJ0aWNsZS9hbXAvaWRVU0tCTjFZSjA5Nw?oc=5

2019-12-15 10:05:00Z
CBMinQFodHRwczovL3d3dy5yZXV0ZXJzLmNvbS9hcnRpY2xlL3VzLWdsb2JhbC1oZWRnZWZ1bmRzLXN1c3RhaW5hYmxlLWFuYWx5c2kvdmlsbGFpbnMtb3ItdmlzaW9uYXJpZXMtaGVkZ2UtZnVuZHMtc2hvcnQtY29tcGFuaWVzLXRoZXktc2F5LWdyZWVud2FzaC1pZFVTS0JOMVlKMDk30gE0aHR0cHM6Ly9tb2JpbGUucmV1dGVycy5jb20vYXJ0aWNsZS9hbXAvaWRVU0tCTjFZSjA5Nw

Sabtu, 14 Desember 2019

In surprise decision, US approves muscular dystrophy drug - The Associated Press

WASHINGTON (AP) — U.S. health regulators approved a second drug for a debilitating form of muscular dystrophy, a surprise decision after the medication was rejected for safety concerns just four months ago.

The ruling marks the second time the Food and Drug Administration has granted preliminary approval for the disease based on early results and is likely to stoke questions about its standards for clearing largely unproven medications.

The FDA said late Thursday it approved Sarepta Therapeutics’ Vyondys 53 for patients with a form of Duchenne’s muscular dystrophy. Duchenne’s affects about 1 in every 3,600 boys in the U.S., causing muscle weakness, loss of movement and early death, usually when patients are in their 20s or 30s. The drug is for a specific type that affects about 8 percent of boys with Duchenne’s.

In August, the FDA appeared to reject the injectable medication, sending a letter to the company that flagged risks of infections and cases of kidney injury in animal studies. But Sarepta disputed the decision, raising it to FDA’s drug center leadership. The company resubmitted its application and data, and the FDA reversed its decision, according to a Sarepta press release.

The FDA said Thursday doctors should monitor the kidney function of patients taking the drug. The drug’s most common side effects include headache, fever, abdominal pain and nausea. Other reactions include rash, fever, hives and skin irritation.

The surprise approval sent company shares rocketing more than 36% in trading Friday. But some Wall Street analysts said the approval suggests loosening standards at the agency.

“The abruptness of the decision making at the agency does not inspire confidence, in our view,” analyst Debjit Chattopadhyay wrote in a note to investors.

It’s the second time a Sarepta drug has followed an unusual path to approval. In 2016, FDA leaders cleared the company’s first muscular dystrophy drug, overruling agency reviewers who said there was little evidence it worked. The decision also followed an intense lobbying campaign by patients’ families, politicians and physicians. Agency critics suggested the FDA may have bowed to outside pressure.

Vyondys received “accelerated approval” based on preliminary results showing it boosts a protein that aids the growth of muscle fibers. But the drug has not yet been shown to improve patients’ mobility or health. The FDA is requiring Sarepta to conduct followup studies on those measures for both drugs. If the company fails to show the drugs help patients, the FDA can withdraw approval — though it rarely does so.

The follow-up study for Vyondys is due by 2024. The drug will cost $300,000 per year for the typical patient — a child weighing 44 pounds, the company said. That’s the same price as Sarepta’s earlier drug.

Analysts said the unexpected decision could bode well for other experimental drugs with questionable study results, including a closely watched drug Alzheimer’s drug that will soon come before the agency.

The drug’s developers reported results in October suggesting their medication could be the first to slow mental decline in Alzheimer’s. But many experts are skeptical, noting unusual study changes and analyses used during the drug’s development.

___

Follow Matthew Perrone on Twitter: @AP_FDAwriter

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Let's block ads! (Why?)


https://news.google.com/__i/rss/rd/articles/CBMiM2h0dHBzOi8vYXBuZXdzLmNvbS9jYmY5OTUxOWNlYTNjNjc2MmE3ZGMzNmY3YmM1NTE0MdIBAA?oc=5

2019-12-14 14:52:34Z
52780491861667

In surprise decision, US approves muscular dystrophy drug - The Associated Press

WASHINGTON (AP) — U.S. health regulators approved a second drug for a debilitating form of muscular dystrophy, a surprise decision after the medication was rejected for safety concerns just four months ago.

The ruling marks the second time the Food and Drug Administration has granted preliminary approval for the disease based on early results and is likely to stoke questions about its standards for clearing largely unproven medications.

The FDA said late Thursday it approved Sarepta Therapeutics’ Vyondys 53 for patients with a form of Duchenne’s muscular dystrophy. Duchenne’s affects about 1 in every 3,600 boys in the U.S., causing muscle weakness, loss of movement and early death, usually when patients are in their 20s or 30s. The drug is for a specific type that affects about 8 percent of boys with Duchenne’s.

In August, the FDA appeared to reject the injectable medication, sending a letter to the company that flagged risks of infections and cases of kidney injury in animal studies. But Sarepta disputed the decision, raising it to FDA’s drug center leadership. The company resubmitted its application and data, and the FDA reversed its decision, according to a Sarepta press release.

The FDA said Thursday doctors should monitor the kidney function of patients taking the drug. The drug’s most common side effects include headache, fever, abdominal pain and nausea. Other reactions include rash, fever, hives and skin irritation.

The surprise approval sent company shares rocketing more than 36% in trading Friday. But some Wall Street analysts said the approval suggests loosening standards at the agency.

“The abruptness of the decision making at the agency does not inspire confidence, in our view,” analyst Debjit Chattopadhyay wrote in a note to investors.

It’s the second time a Sarepta drug has followed an unusual path to approval. In 2016, FDA leaders cleared the company’s first muscular dystrophy drug, overruling agency reviewers who said there was little evidence it worked. The decision also followed an intense lobbying campaign by patients’ families, politicians and physicians. Agency critics suggested the FDA may have bowed to outside pressure.

Vyondys received “accelerated approval” based on preliminary results showing it boosts a protein that aids the growth of muscle fibers. But the drug has not yet been shown to improve patients’ mobility or health. The FDA is requiring Sarepta to conduct followup studies on those measures for both drugs. If the company fails to show the drugs help patients, the FDA can withdraw approval — though it rarely does so.

The follow-up study for Vyondys is due by 2024. The drug will cost $300,000 per year for the typical patient — a child weighing 44 pounds, the company said. That’s the same price as Sarepta’s earlier drug.

Analysts said the unexpected decision could bode well for other experimental drugs with questionable study results, including a closely watched drug Alzheimer’s drug that will soon come before the agency.

The drug’s developers reported results in October suggesting their medication could be the first to slow mental decline in Alzheimer’s. But many experts are skeptical, noting unusual study changes and analyses used during the drug’s development.

___

Follow Matthew Perrone on Twitter: @AP_FDAwriter

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Let's block ads! (Why?)


https://news.google.com/__i/rss/rd/articles/CBMiM2h0dHBzOi8vYXBuZXdzLmNvbS9jYmY5OTUxOWNlYTNjNjc2MmE3ZGMzNmY3YmM1NTE0MdIBAA?oc=5

2019-12-14 12:41:05Z
52780491861667

Bath & Body Works announces Saturday 'Body Care Day' sale: $4.95 personal-care products - USA TODAY

Bath & Body Works has announced a first-of-its-kind "Body Care Day" sale to be held Saturday, December 14, which will include all personal care fragrances and collections .

The one-day sale will be available in stores and online, with many retail locations open for extended hours, according to a Friday release.

"On December 14, for one day only, ALL Body Care lines are $4.95 – that's up to a 70% discount," the release says.

The sale will apply to nearly 600 personal-care products, including three fragrances that will debut or return Saturday: Christmas Cocoa & Mint, Black Amethyst, and Pink Velvet Cupcake.

Among the personal-care products on sale: moisturizers, cleansers, and fragrances. The retailer's Men's Collection is also included in the sale.

"Body Care Day" follows last weekend's "Candle Day sale," held on Dec. 7 — the brand's sixth-annual made-up holiday, which Bath & Body Works' called its "biggest event of the season and the most highly anticipated day of the year for brand loyalists and candle aficionados." 

Search for hours using the store locator at www.bathandbodyworks.com/store-locator.

Bath & Body Works isn't the only retailer trying to attract customers with mid-December deals. Recently numerous retailers, including Best Buy, have begun '12 Days of Deals' promotions ahead of Christmas.

Contributing: Kelly Tyko, USA TODAY

Let's block ads! (Why?)


https://news.google.com/__i/rss/rd/articles/CBMicWh0dHBzOi8vd3d3LnVzYXRvZGF5LmNvbS9zdG9yeS9tb25leS8yMDE5LzEyLzEzL2JhdGgtYm9keS13b3Jrcy1ib2R5LWNhcmUtZGF5LWJvZHktY2FyZS1zYWxlLXNhdHVyZGF5LzI2NDI3OTAwMDEv0gEnaHR0cHM6Ly9hbXAudXNhdG9kYXkuY29tL2FtcC8yNjQyNzkwMDAx?oc=5

2019-12-14 07:21:02Z
52780494203876

Bath & Body Works announces Saturday 'Body Care Day' sale: $4.95 personal-care products - USA TODAY

Bath & Body Works has announced a first-of-its-kind "Body Care Day" sale to be held Saturday, December 14, which will include all personal care fragrances and collections .

The one-day sale will be available in stores and online, with many retail locations open for extended hours, according to a Friday release.

"On December 14, for one day only, ALL Body Care lines are $4.95 – that's up to a 70% discount," the release says.

The sale will apply to nearly 600 personal-care products, including three fragrances that will debut or return Saturday: Christmas Cocoa & Mint, Black Amethyst, and Pink Velvet Cupcake.

Among the personal-care products on sale: moisturizers, cleansers, and fragrances. The retailer's Men's Collection is also included in the sale.

"Body Care Day" follows last weekend's "Candle Day sale," held on Dec. 7 — the brand's sixth-annual made-up holiday, which Bath & Body Works' called its "biggest event of the season and the most highly anticipated day of the year for brand loyalists and candle aficionados." 

Search for hours using the store locator at www.bathandbodyworks.com/store-locator.

Bath & Body Works isn't the only retailer trying to attract customers with mid-December deals. Recently numerous retailers, including Best Buy, have begun '12 Days of Deals' promotions ahead of Christmas.

Contributing: Kelly Tyko, USA TODAY

Let's block ads! (Why?)


https://news.google.com/__i/rss/rd/articles/CBMicWh0dHBzOi8vd3d3LnVzYXRvZGF5LmNvbS9zdG9yeS9tb25leS8yMDE5LzEyLzEzL2JhdGgtYm9keS13b3Jrcy1ib2R5LWNhcmUtZGF5LWJvZHktY2FyZS1zYWxlLXNhdHVyZGF5LzI2NDI3OTAwMDEv0gEnaHR0cHM6Ly9hbXAudXNhdG9kYXkuY29tL2FtcC8yNjQyNzkwMDAx?oc=5

2019-12-14 07:18:45Z
52780494203876

Jumat, 13 Desember 2019

US retail sales rose less than expected 0.2% in November - CNBC

U.S. retail sales increased less than expected in November as Americans cut back on discretionary spending, which could see economists dialing back economic growth forecasts for the fourth quarter.

The Commerce Department said on Friday retail sales rose 0.2% last month. Data for October was revised up to show retail sales increasing 0.4% instead of gaining 0.3% as previously reported.

Economists polled by Reuters had forecast retail sales would accelerate 0.5% in November. Compared to November last year, retail sales increased 3.3%.

Excluding automobiles, gasoline, building materials and food services, retail sales edged up 0.1% last month after rising by an unrevised 0.3% in October.

The so-called core retail sales correspond most closely with the consumer spending component of gross domestic product. Consumer spending, which accounts for more than two-thirds of U.S. economic activity, grew at a 2.9% annualized rate in the third quarter.

The economy expanded at a 2.1% pace in the July-September period. Last month's small increase in core retail sales could see economists lower their GDP growth estimates for the fourth quarter, which are currently converging around a rate of 1.8%.

The report bucked a recent raft of fairly upbeat economic data on the labor market, housing, trade and manufacturing that had suggested the economy was growing at a moderate speed despite headwinds from trade tensions and slowing global growth.

The Federal Reserve on Wednesday kept interest rates steady and signaled that borrowing costs were likely to remain unchanged at least through next year amid expectations the economy would continue to grow modestly and the unemployment rate remains low.

The government reported last week that the economy created 266,000 jobs in November and the unemployment rate fell back to 3.5%, its lowest level in nearly half a century.

Last month, auto sales increased by 0.5% after rising 1.0% in October. Higher gasoline prices lifted receipts at service stations by 0.7%. Online and mail-order retail sales increased by 0.8% after gaining 0.6% in October.

Sales at electronics and appliance stores were up 0.7%. Receipts at building material stores were unchanged and sales at clothing stores fell 0.6%. Spending at furniture stores edged up 0.1%.

Americans cut back on spending at restaurants and bars, with sales falling 0.3%. Spending at hobby, musical instrument and book stores dropped 0.5%.

Let's block ads! (Why?)


https://news.google.com/__i/rss/rd/articles/CBMiQmh0dHBzOi8vd3d3LmNuYmMuY29tLzIwMTkvMTIvMTMvdXMtcmV0YWlsLXNhbGVzLW5vdmVtYmVyLTIwMTkuaHRtbNIBRmh0dHBzOi8vd3d3LmNuYmMuY29tL2FtcC8yMDE5LzEyLzEzL3VzLXJldGFpbC1zYWxlcy1ub3ZlbWJlci0yMDE5Lmh0bWw?oc=5

2019-12-13 13:30:00Z
52780494152701

Facebook Tumbles as FTC Mulls an Injunction – Is the Company’s Dissolution on the Cards? - Wccftech

The Federal Trade Commission (FTC) may use a preliminary injunction to halt Facebook’s (NASDAQ:FB) ongoing efforts toward achieving a tighter integration between its messaging apps: Instagram, Messenger and WhatsApp.

According to the reporting by the Wall Street Journal, the impetus behind a possible injunction has grown stronger over the past few months amid fears that Facebook’s integration campaign may make it difficult, if not impossible, to break up the company in any future antitrust action.

As per an internal source of the Journal, the FTC may invoke the “interoperability” rules as a basis for an injunction and to highlight the potential detrimental impact of Facebook’s integration push on the ability of other industry players to compete.

It is important to note that this decision by the FTC will require a favorable majority vote. Currently, 3 Republicans and 2 Democrats constitute the membership of the commission. Consequently, in order to impose an injunction on Facebook, the vote will have to be carried by at least 3 FTC members.

As a refresher, Facebook first announced its plans for a tighter stitch between its apps earlier this year. The social media giant’s CEO Mark Zuckerberg wrote in a blog post: “People want to be able to choose which service they use to communicate with people. We want to give people a choice so they can reach their friends across these networks from whichever app they prefer.”

The tech giant’s concurrent efforts to introduce end-to-end encryption on all of its messaging apps has emerged as another thorny issue. Attorney General William Barr has voiced his concerns that this step will provide a safe haven to criminals and make it harder for law enforcement agencies to detect online crimes such as instances of child exploitation. Facebook, for it part, has asserted that its encryption of chats and messages is a necessary component of its targeted efforts for enhancing user privacy.

This development follows growing anger in Washington over the lack of comprehensive scrutiny at the time Facebook purchased WhatsApp and Instagram. In a Twitter post earlier this year, Democratic Representative Ro Khanna wrote: “This is why there should have been far more scrutiny during Facebook’s acquisitions of Instagram and WhatsApp which now clearly seem like horizontal mergers that should have triggered antitrust scrutiny.”

Interestingly, in addition to an ongoing probe by the FTC, Facebook is also facing a separate investigation by the Justice Department as well as another antitrust probe from a coalition of 47 state attorneys general.

In light of this report by the Wall Street Journal, Facebook’s stock tumbled over 2 percent on Thursday to close at $196.75. For context, the tech giant currently has a market capitalization of $556.37 billion. Year-to-date, the stock has posted gains of 50.09 percent against the broader gains by the S&P500 of 26.40 percent.

Submit

Let's block ads! (Why?)


https://news.google.com/__i/rss/rd/articles/CBMiamh0dHBzOi8vd2NjZnRlY2guY29tL2ZhY2Vib29rLXR1bWJsZXMtYXMtZnRjLW11bGxzLWFuLWluanVuY3Rpb24taXMtdGhlLWNvbXBhbnlzLWRpc3NvbHV0aW9uLW9uLXRoZS1jYXJkcy_SAW5odHRwczovL3djY2Z0ZWNoLmNvbS9mYWNlYm9vay10dW1ibGVzLWFzLWZ0Yy1tdWxscy1hbi1pbmp1bmN0aW9uLWlzLXRoZS1jb21wYW55cy1kaXNzb2x1dGlvbi1vbi10aGUtY2FyZHMvYW1wLw?oc=5

2019-12-13 12:00:42Z
52780492243490